Kenneth Frazier, the CEO of the pharmaceutical company known as MSD outside of North America, discusses his upbringing and how it influences his leadership as chief executive. He is one of the few African-American CEOs in the Fortune 500, and shot to prominence after resigning from a council advising the Trump White House. Frazier discusses the importance of values in leadership and how Merck thinks about R&D and drug prices.

AP Photo/Alex Brandon

• The federal government on Saturday announced initial plans for distributing a promising coronavirus drug, remdesivir.
• The drug, manufactured by Gilead Sciences, was authorized for emergency use last week, but doctors and hospitals weren't sure how they were going to get it.
• The Department of Health and Human Services now say the drug is first being distributed to health departments in some hard-hit states, and the departments can distribute it to hospitals as they see fit. 
• Eventually, HHS expects the drug to be delivered to all 50 states, terrorities, the Veterans Health Administration and the Indian Health Service. 
• Visit Business Insider's homepage for more stories.

The federal government released its initial distribution plans today for the promising coronavirus drug, remdesivir, which was approved for emergency use last week. 

The drug, donated by manufacturer Gilead Sciences, "will be used to treat hospitalized COVID-19 patients in areas of the country hardest hit by the pandemic," the US Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) said in a press release.

See the rest of the story at Business Insider

NOW WATCH: How the Navy's largest hospital ship can help with the coronavirus

See Also:

• The coronavirus drug remdesivir was OK'd for emergency use a week ago. The plan to get it to patients is still mired in confusion.
• Dispensed: Hospitals are stuck waiting for a promising coronavirus treatment
• 'It's hard to pay off your medical school loans in this kind of a job': Doctors who can protect the world against pandemics are in short supply

The study, published in the journal Pathogens, found that all four drugs were effective in inhibiting, or blocking, the coronavirus' RNA proteins from making genomic copies of the novel coronavirus.

The owner of a Detroit-area physical therapy clinic was sentenced to 11 years in prison today for his role in a drug diversion scheme.

Former President of Venezuela Nicolás Maduro Moros, Venezuela’s vice president for the economy, Venezuela’s Minister of Defense, and Venezuela’s Chief Supreme Court Justice are among those charged in New York City; Washington, DC; and Miami, along with current and former Venezuelan government officials as well as two Fuerzas Armadas Revolucionarias de Colombia (FARC) leaders, announced U.S. Attorney General William P. Barr, U.S. Attorney Geoffrey S. Berman of the Southern District of New York, U.S. Attorney Ariana Fajardo Orshan of the Southern District of Florida, Assistant Attorney General Brian A. Benczkowski of the Justice Department’s Criminal Division, Acting Administrator Uttam Dhillon of the U.S. Drug Enforcement Administration (DEA) and Acting Executive Associate Director Alysa D. Erichs of U.S. Immigration and Customs Enforcement’s Homeland Security Investigations (HSI).

Perhaps when COVID-19 is done and dusted the Victorian Government might apply some of the same tough, no nonsense attitude towards getting drug drivers off our roads.

Kalydeco is the first medicine in Europe to treat the underlying cause of the disease

A library of macrocyclic compounds of the formula (I) where part (A) is a bivalent radical, a —(CH2)y— bivalent radical or a covalent bond;where part (B) is a bivalent radical, a —(CH2)z— bivalent radical, or a covalent bond;where part (C) is a bivalent radical, a —(CH2)t— bivalent radical, or a covalent bond; andwhere part (T) is a —Y-L-Z— radical wherein Y is CH2 or CO, Z is NH or O and L is a bivalent radical. These compounds are useful for carrying out screening assays or as intermediates for the synthesis of other compounds of pharmaceutical interest. A process for the preparation of these compounds in a combinatorial manner, is also disclosed.

The present disclosure relates to compositions and methods for producing nanoparticles to provide relatively more rapid delivery of such particles across the blood-brain barrier. The nanoparticles may be formed from bis-quaternary pyridinium-aldoxime salts that may also be of a specific polymorphic structure and which may be formed in either hydrophobic or hydrophilic type liquid media. In addition, the nanoparticle for transport across the blood-brain barrier may comprise a polymeric resin encapsulating a bis-quaternary pyridinium-2-aldoxime salt.

The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.

The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis. Molecular flux rates within the one or more biochemical processes serve as biomarkers and are quantitated and compared with the molecular flux rates (i.e., biomarker) from control subjects (i.e., subjects not exposed to the compounds). Any change in the biomarker in the subject relative to the biomarker in the control subject provides information to evaluate therapeutic efficacy of an administered drug or a toxic effect and to develop the compound further if desired. In one aspect of the invention, stable isotope-labeled substrate molecules are administered to a subject and the label is incorporated into targeted molecules in a manner that reveals molecular flux rates through metabolic pathways of interest.

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

The present invention relates to methods for synthesizing compounds of formula I or pharmaceutically acceptable salts thereof: I wherein each of X, Alk1, Alk2, and W are as defined and described herein.

It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide (“AMP”) and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain which typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, with a member of a diverse class of antimicrobial agents currently validated in preclinical and clinical settings for the treatment of a broad spectrum of pathogenic organisms.

Devices capable of deterring or preventing bulk extraction of drugs from, for example, drug-delivery systems are exemplarily disclosed. In one embodiment, such a device may include a package releasably retaining a drug and an agent. The agent is configured to suppress a physiological effect of the drug when the agent contacts the drug or is coadministered with the drug. The cell package is configured such that an amount of the drug is selectively releasable with respect to the agent when the package is operably proximate to an encoded key. The package, however, may be configured to impose a relatively high likelihood that either the drug will not be accessed or the drug will be contaminated by the agent if access to the contents of the package is sought without the use of an encoded key.

A method of enabling administration of a drug includes determining, within a drug-transfer device including cells, a location of at least one cell and generating information identifying the determined location. A user may be provided with the drug-transfer device. The drug is retained within the at least one cell when the user is provided with the drug-transfer device. The method also includes encoding a key with the information and providing the user with the key before, after or when the user is provided with the drug-transfer device. Drug retained within the at least one cell is selectively releasable when the key is operably proximate to the drug-transfer device and is encoded with the information. The key can be encoded with the information before and/or after being provided to the user. In some embodiments, the key is encoded based on instructions transmitted over a network.

A peptide comprising a sequence for opening a tight junction of an epithelial surface and optionally a cell penetrating sequence; and related compositions, optionally comprising further pharmaceutical agents; and related methods.

An assembly for a counter mechanism for a drug delivery device is described comprising a drive member, wherein the drive member is adapted and arranged to be rotated in a first rotational direction and to be prevented from rotation in a second rotational direction which direction is opposite to the first rotational direction, an advancing member adapted and arranged to be axially moved and rotated with respect to the drive member, wherein the advancing member is adapted and arranged to mechanically cooperate with the drive member such that the drive member is rotated in the first rotational direction, and a display member which is configured to count a number of doses and to display the counted number of doses, wherein the assembly is adapted and arranged such that rotation of the drive member in the first rotational direction is converted into a counting movement of the display member. Furthermore, a drug delivery device comprising the assembly is described.

An assembly for a drug delivery device (1) is proposed, comprising a housing (13) having a proximal end and a distal end, a dose member (23) which is displaceable in the proximal direction with respect to the housing for setting of a dose of a drug, a clutch member (28) which is displaced in the proximal direction with respect to the housing when setting the dose, and a stop member (30) configured to define a clutch stop position for the proximal displacement of the clutch member with respect to the housing, with the clutch member, when in the clutch stop position, being prevented from further displacement in the proximal direction with respect to the housing, wherein the clutch member and the dose member are configured to mechanically cooperate with one another when the clutch member is in the clutch stop position, thereby preventing further displacement of the dose member in the proximal direction with respect to the housing during setting of the dose. Furthermore, a drug delivery device (1) is proposed.

An add-on logging device (100, 300) mounted to a drug delivery device is turned on when the cap is removed. After a given amount of time in inactivity the sensor means of the add-on device is turned off automatically to save energy. If the user takes a dose of drug this is not detected as the add-on device is only turned on when the cap is removed. According to the present invention a warning message is provided when the cap is re-mounted after the sensor means has been turned off automatically, the warning message indicating to a user that an expelled dose may not have been detected.

The invention is directed to a dose indicating mechanism for drug delivery device (1) configured for the delivery of a medicament contained in single medicament cartridge (2), the medicament comprising at least one first drug and one second drug, wherein the dose indicating mechanism comprises a body (3), a dose dial component (7) configured to move relative to the body (3) during dose setting and first dose indicator means (10) configured to display a set dose of the medicament and/or of first drug in dependence of the displacement of dose dial component (7) during dose setting. In order to provide the user with further information, a second dose indicator means (15) is provided that is configured to display a set dose of the second drug during dose setting. The invention is also directed to a respective drug delivery device.

A drug delivery device is provided herein, the device including a reservoir for containing a medicament. The medicament includes a suspension of solids in a liquid carrier. The device also includes a needle having a distal end for injection into a patient, a proximal end in communication with the reservoir, and a lumen extending between the distal and proximal ends. A path is defined from the reservoir to the distal end of the needle through the lumen, the path having an inner diameter that decreases in a proximal to distal direction along at least a portion thereof. Advantageously, with the subject invention, a flow path may be defined which provides a more gradual transition in diameter from the reservoir to a distal tip of the needle. In this manner, changes in velocity of the suspension may be less abrupt than in the prior art, thus better maintaining solid particles in the suspension.

A drug delivery balloon apparatus is disclosed herein, comprising: (a) at least two lumens, comprising a first lumen and a second lumen, (b) a balloon inflation port in fluid communication with the first lumen, (c) a drug delivery port in fluid communication with the second lumen, (d) a guidewire port in fluid communication with the second lumen, wherein the second lumen is configured to receive both a guidewire and a drug solution, (e) an occlusion balloon, (I) a drug delivery balloon, where the occlusion balloon and the drug delivery balloon are in fluid communication with the first lumen, (g) one or more drug delivery channels extending the length of the second lumen, and (h) one or more drug delivery ducts extending from the one or more drug delivery channels to an exterior surface of the second lumen.

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, nutraceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures.

A transdermal drug delivery device comprises: a reservoir for holding a drug; and at least one microneedle in fluid communication with the reservoir through which the drug can be delivered transdermally, wherein the transdermal drug delivery device is concealed from view during operation thereof.

The present invention provides assays for detecting and measuring the presence or level of anti-TNFα drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFα drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug.

Methods for multiplexed delivery of agents to a solid tissue in vivo followed by assessment of efficacy with mass spectrometry are described.

A WOMAN has been banned from the road for drug driving.

RETIRED engineer Brian Cramp is a medical pioneer.

Microbes are the bacteria that live in our guts. Scientists are learning how they help us process medication.

The so-called evidence collected by fan of the 'Shortie Like Mine' hitmaker's rumored drug abuse confirms an Instagram thot's claim that they were high on whippets during a drug-filled night out in April.

Authorities seized 400 grams of fentanyl during two investigations in Nassau County this week.

Conservatives demand council and police act on growing menace.

Promoters back way forward to help Birmingham nightlife.

Use the bins

How a baggie of crack cocaine packed with fear, distortion and misconceptions, and one presidential address in the 1980s, helped shape the war on drugs.

*
*Don’t miss out on the next big story. Get the Weekly Reveal newsletter today.

How a baggie of crack cocaine packed with fear, distortion and misconceptions, and one presidential address in the 1980s, helped shape the war on drugs.

Don’t miss out on the next big story. Get the Weekly Reveal newsletter today.

Emily Ligawiec has to sign in visitors to the recovery program she attends in a grand Victorian house in Holyoke, Mass. She can't bring people to her room. She only recently earned phone and car privileges. "We get 24, 48, 72-hour passes every weekend," she said. But Ligawiec doesn't mind the restrictions. The 29-year-old is grateful she's alive to follow them, after a decade of addiction — first to prescription painkillers, then pills she bought in the street, then heroin. "I had gone down a pretty dark path," she said. What finally turned her around was a 911 call last winter. She had gotten high on heroin and stolen her mother's car. When she returned it a few hours later, Officer John Cacela of Ware, Mass., was waiting in the driveway. In the past, Cacela might have immediately read Ligawiec her rights, "because for the longest time, the whole idea was — arrest, arrest," he said. Instead, he tapped on the car window and assured her she wasn't in trouble. "I closed the window on him

http://www.musicxray.com/xrays/1319824 Luh Guccii - Luh Guccii ft. Kevo - Fix it up(everday off the drugs)

Swami Sivananda who was a medical doctor by profession shares with us simple and cheap remedies for common ailments..

This item belongs to: texts/opensource.

This item has files of the following types: Archive BitTorrent, Metadata, Text PDF

Prescription drugs can cost a fortune. One reader wonders aloud about saving money on brand-name medicine.

One of the hottest debates in the coronavirus pandemic is whether the malaria drugs promoted as possible treatments by President Donald Trump really work. But Americans don’t seem overly eager to help answer the question. Enrollment in several clinical trials of chloroquine and hydroxychloroquine — including two by the University of Washington — has been […]

One of the hottest debates in the coronavirus pandemic is whether the malaria drugs promoted as possible treatments by President Donald Trump really work. But Americans don’t seem overly eager to help answer the question. Enrollment in several clinical trials of chloroquine and hydroxychloroquine — including two by the University of Washington — has been […]

One of the hottest debates in the coronavirus pandemic is whether the malaria drugs promoted as possible treatments by President Donald Trump really work. But Americans don’t seem overly eager to help answer the question. Enrollment in several clinical trials of chloroquine and hydroxychloroquine — including two by the University of Washington — has been […]

The swift embrace and rapid abandonment of hydroxychloroquine underlines how publicity of evolving science can have unpredictable consequences. And how supply chains and government agencies struggle to keep up.

One of the hottest debates in the coronavirus pandemic is whether the malaria drugs promoted as possible treatments by President Donald Trump really work. But Americans don’t seem overly eager to help answer the question. Enrollment in several clinical trials of chloroquine and hydroxychloroquine — including two by the University of Washington — has been […]

TOKYO (AP) — Asian shares advanced on Thursday, riding a wave of optimism about a possible treatment for the coronavirus that set off a rally on Wall Street powerful enough to override data showing the U.S. economy had logged its worst quarterly performance since 2009. Japan’s benchmark Nikkei 225 surged 2.6% in morning trading to […]